Advertisement
A case of racism by a patient that disrupted the power dynamics between a physician and patient is described in a reflection piece published in the May/June issue of the Annals of Family Medicine.

Racism Can Disrupt Physician-Patient Power Dynamics

0
But black female physician notes that she has the power and privilege to leave a given situation
Overweight colorectal cancer patients may have better survival than their normal-weight peers

Overweight Colorectal CA Patients Display Better Survival Odds

0
Overweight, but not obese, patients found to be less likely to die
The number of pregnant women in the United States infected with the Zika virus has just tripled because cases are now being counted in a more comprehensive way

CDC: New Method of Identifying Pregnant Women With Zika Virus

0
Registries will track those who show lab evidence of infection, whether or not they ever had symptoms
Strategies can be employed to maximize the amount of time available for patient care by streamlining revenue-related processes

Strategies Can Help Streamline Revenue-Related Processes

0
They can be employed to help maximize amount of time available for patient care
Survival odds for colorectal cancer may depend on which side of the colon the primary tumor develops

ASCO: Side of Colon Tumor Develops on Affects CRC Survival

0
Patients with primary tumors on left side live longer than those with primary tumors on right
Palliative care that's offered soon after a terminal cancer diagnosis can also help caregivers

ASCO: Early Palliative Care Beneficial for Caregivers

0
Such programs improve quality of life for people caring for terminal cancer patients

American Thoracic Society, May 13-18

0
The American Thoracic Society's 2016 International Conference The annual meeting of the American Thoracic Society was held from May 13 to 18 in...
Use of pembrolizumab (Keytruda) in advanced melanoma is extending survival for many and even curing some

ASCO: Pembrolizumab Improves Survival in Melanoma

0
Three-year overall survival rate of 40 percent; median overall survival of 24.4 months
The U.S. Food and Drug Administration has approved atezolizumab (Tecentriq)

FDA Approves Tecentriq to Treat Urothelial Carcinoma

0
FDA also approves a companion test to detect PD-L1 protein expression levels in patients
Self-measured waist circumference has a clinically important false-negative rate compared with professionally-measured waist circumference

Self-Measured Waist Circumference Often Falls Short

0
Clinically important false-negative rate for self-measured waist circumference